Skin Oncology Firm MedC Biopharma Launches on DealSquare
December 03 2020 - 9:55AM
MedC Biopharma Corporation (“MedC”), a science-driven company
that develops, produces and delivers innovative skin oncology
medication worldwide, today announced the launch of its $3 million
listing on DealSquare ($MEDCB). Powered by NEO technology,
DealSquare is a joint initiative between Silver Maple Ventures and
NEO to make private markets better and more accessible.
A clinical-stage biopharmaceutical company, MedC
develops and commercializes cannabinoid and other natural
compound-containing products for use in the consumer, veterinary,
medical skin, and general health markets. The company has already
developed two drugs toward clinical trials for CTCL – Skin
(Cutaneous) T-cell Lymphoma and Cutaneous Leishmaniasis, both of
which are recognized as orphan conditions with unmet needs, and as
markets with huge potential. MedC is developing its own proprietary
red sea-algae “Algel” gel-based products, with a variety of
applicable uses for skin health and wellness, and is also pursuing
opportunities in veterinary medication and pet health, specifically
oncology and inflammation-related indications (an estimated $400
million annual market).
MedC’s listing on DealSquare creates an opportunity
for investors who believe there is a global need to mature and
legitimize the cannabis and cannabis-related health and medical
market, by supporting the development of products that deliver
health and wellness benefits. With the funds raised from this
listing, MedC is targeting international expansion, initially
across Canada and Australia, with plans to launch in Europe, UK,
Asia, and Latin America shortly thereafter. It will also expand its
product offering with new lines for different markets and multiple
dose formats. There will be a strong focus on research and
development of high value market products, as well as regulatory
work, thus enabling MedC to further enhance its product
offering.
“The launch of our private offering on DealSquare
marks a significant step towards MedC taking its place amongst
industry leaders that are determined to legitimize and deliver the
health benefits of cannabinoids to the global community,” remarked
Dr. Owen Van Cauwenberghe, President of MedC. “Our tireless efforts
and commitment to substantiated medical and health claims for these
products will ensure that their benefits will be available to all
those in need. We are fortunate that DealSquare recognizes our
potential and is providing a centralized platform to support our
continued efforts.”
DealSquare is an online private placement platform
for dealers, investment advisors, and capital raisers. The
centralized platform gives registered users the ability to
efficiently find, analyze, share, and subscribe to private market
deals. DealSquare offers a fully digital and automated process,
allowing capital raisers to publish their private placement
opportunities, dealers to complete their due diligence, and
advisors and investors to electronically subscribe to a deal.
Exempt securities are seamlessly integrated into client accounts
and dealer back office systems using NEO technology.
“We welcome MedC onto DealSquare. The
cannabis-related health and medical market is a fast-growing market
that offers attractive investment opportunities,” said Peter-Paul
Van Hoeken, Managing Director of DealSquare, “The listing of MedC
on DealSquare enables dealers and advisors to offer this investment
opportunity to their clients, and to execute investments
efficiently and in a fully digitized way through our online
platform.”
“Like DealSquare and NEO, MedC is on a relentless
pursuit of innovation for the benefit of others,” commented Jos
Schmitt, President and CEO of NEO. “They are well-positioned to
deliver effective medical treatments for skin conditions in a
highly underserviced market, and the funds raised from this
DealSquare campaign will help make that possible. We are excited to
help MedC raise the capital needed to achieve rapid growth, while
providing investors with a unique investment opportunity that would
otherwise be inaccessible.”
To view MedC Biopharma’s private placement offering
on DealSquare, click here. The MedC Biopharma ticker is available
under MEDCB on existing advisor order entry systems.
About MedC
Biopharma
MedC Biopharma is a science-driven company focused
on developing, producing, and delivering differentiated cannabinoid
and other natural compound-containing products targeting the
consumer, veterinary and medical skin & general health
markets.
Connect with MedC Biopharma: Website | LinkedIn
About DealSquare
A joint initiative between NEO and Silver Maple
Ventures, DealSquare, is Canada’s first centralized dealer platform
for private placements, digitally connecting capital-raisers to
investment dealers, their advisory networks, and their investors.
With the complete roll-out of the platform in early 2020,
DealSquare supports the entire private placement process: capital
raisers publish their private placement opportunities; dealers
complete their due diligence; and advisors electronically subscribe
to a deal, with exempt securities seamlessly integrated into client
accounts and back office systems utilizing NEO technology.
Connect with DealSquare: Website | LinkedIn |
Twitter
About NEO
NEO is a group of established fintech companies
that provide capital markets infrastructure designed for and led by
the industry. NEO’s competitive drive, innovation, and advocacy
enable change for the better. The NEO Exchange is a progressive
stock exchange that brings together investors and capital raisers
within a fair, efficient, and service-oriented environment; and
DealSquare, powered by NEO technology, is a platform that enables
the distribution of financial assets not listed on a stock exchange
in a way that reduces costs, minimizes operational risks, and
improves the investor experience.
Connect with NEO: Website |
Twitter | LinkedIn
About Silver Maple Ventures
Silver Maple Ventures Inc. (“SMV”) is an exempt
market dealer and holding company of FrontFundr Financial Services
Inc. (“FrontFundr”) and DealSquare Technologies Inc.
(“DealSquare”). With offices in Toronto and Vancouver, the SMV
team are national leaders in the private capital markets,
developing and operating two fintech platforms to provide access to
private markets in Canada and simplify the transaction process.
Media Contact
John Hills
E: John@dealsquare.io
P: 289 962 1708